Abstract: A method for forming a composite part includes providing a core (22), providing a set of fiber bands (24), placing the set of fiber bands (24) in a set of predetermined positions, and fixing the set of fiber bands (24) at the set of predetermined positions through the use of a binder material, such as resin.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: A method of combining object data captured from an object, the method comprising: receiving first object data and second object data, the first and second object data comprising intensity image data and three-dimensional geometry data of the object; synthesising a first fused image of the object and a second fused image of the object by fusing the respective intensity image data and the respective three-dimensional geometry data of the object illuminated by a directional lighting arrangement produced by a directional light source, the directional lighting arrangement produced by the directional light source being different to a lighting arrangement used to capture at least one of the first object data and the second object data; aligning the first fused image and the second fused image; and combining the first object data and the second object data.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: A system and method determining a camera pose. The method comprises receiving a first image and a second image, the first and second images being associated with a camera pose and a height map for pixels in each corresponding image, and determining a mapping between the first image and the second image using the corresponding height maps, the camera pose and a mapping of the second image to an orthographic view. The method further comprises determining alignment data between the first image transformed using the determined mapping and the second image and determining a refined camera pose based on the determined alignment data and alignment data associated with at least one other camera pose.

Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic

Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which

Abstract: A kinesthetic speaker usage system provides a speaker connected to a housing about a cavity into which the sound from the speaker is directed. The housing has an exterior surface in tactile communication with a retainer which can direct vibration directly or directly to a user, such as a person. Many embodiments utilize a pipe for the housing, such as a flexible pipe.

Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: A door stop includes a base with a first side member and a second side member extending parallel relative to the first side member; and a joining member integral with the first side member and the second side member that form a c-shaped configuration with an opening. The door stop further includes an elongated rigid body pivotally attached to the first side member and the second side member, the elongated rigid member is configured to fit within the opening; a first groove extending a partial length of a thickness of the first member; a second groove extending a partial length of a thickness of the second member; a first tab extending from the elongated rigid body and configured to rest within the first groove; a second tab extending from the elongated rigid body and configured to rest within the second groove; and a pivot joint having a rod that extend through the first member, through the elongated rigid body, and through the second member.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A21, or, particularly, the A2, receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic

Abstract: The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Abstract: This invention concerns apparatus and a method for authenticating a subject using their eye as an identifying biometric, in particular the shape of their cornea. The apparatus comprises an image projection device to generate and project an image of a pattern, made up of plural discrete points, onto at least a part of the cornea of an eye of the person. An image capture device to capture an image of the pattern of plural discrete points, after reflection in at least a part of the cornea of an eye of the person. And, a computer processor to extract a data set defining the locations of the discrete points in the captured image. The method comprises capturing an image of an illuminated pattern, made up of plural discrete points, after reflection in at least a part of the cornea of an eye of the subject. Comparing the locations of the discrete points in the pattern of the captured image against the locations of the discrete points in the pattern of a reference image.